Immunovant, Inc.

NasdaqGS:IMVT Rapporto sulle azioni

Cap. di mercato: US$4.0b

Immunovant Crescita futura

Future criteri di controllo 2/6

Immunovant prevede che gli utili e i ricavi cresceranno rispettivamente di 8.3% e 75.5% all'anno. Si prevede che l'EPS crescerà di 11.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -175.9% in 3 anni.

Informazioni chiave

8.3%

Tasso di crescita degli utili

11.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.5%
Tasso di crescita dei ricavi75.5%
Rendimento futuro del capitale proprio-175.9%
Copertura analitica

Good

Ultimo aggiornamento20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Jul 18
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:IMVT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/202752-547-401-35011
3/31/202620-494-441-42913
3/31/2025N/A-425-356-34813
9/30/2024N/A-323-272-272N/A
6/30/2024N/A-273-244-243N/A
3/31/2024N/A-259-215-214N/A
12/31/2023N/A-243-211-210N/A
9/30/2023N/A-255-210-210N/A
6/30/2023N/A-245-170-170N/A
3/31/2023N/A-211-188-188N/A
12/31/2022N/A-199-166-165N/A
9/30/2022N/A-177-151-151N/A
6/30/2022N/A-167-151-151N/A
3/31/2022N/A-157-106-106N/A
12/31/2021N/A-138-96-96N/A
9/30/2021N/A-128-87-87N/A
6/30/2021N/A-111-91-91N/A
3/31/2021N/A-107-84-83N/A
12/31/2020N/A-100-84-84N/A
9/30/2020N/A-79-66-65N/A
6/30/2020N/A-73-59-59N/A
3/31/2020N/A-66-53-53N/A
12/31/2019N/A-55-43-43N/A
9/30/2019N/A-52-46-46N/A
6/30/2019N/A-44-32-32N/A
3/31/2019N/A-29-29-29N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che IMVT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che IMVT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che IMVT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di IMVT ( 75.5% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di IMVT ( 75.5% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che IMVT non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita